The prognostic value of galactosylceramide-sulfotransferase (Gal3ST1) in human renal cell carcinoma

Stefan Porubsky1,6, Malin Nientiedt2, Maximilian C. Kriegmair3, Jörn-Helge Heinrich Siemoneit1, Roger Sandhoff3, Richard Jennemann3, Hendrik Borgmann4, Timo Gaiser1, Cleo-Aron Weis1, Philipp Erben2, Thomas Hielscher5 & Zoran V. Popovic1

Renal cell carcinoma (RCC) is the deadliest primary genitourinary malignancy typically associated with asymptomatic initial presentation and poorly predictable survival. Next to established risk factors, tumor microenvironment may alter metastatic capacity and immune landscape. Due to their high concentrations, sulfoglycolipids (sulfatides) were among the first well-described antigens in RCC that are associated with worse prognosis. As sulfatide detection in routine diagnostics is not possible, we aimed to test the prognostic value of its protein counterpart, sulfatide-producing enzyme Gal3ST1. We performed retrospective long-term follow up analysis of Gal3ST1 expression as prognostic risk factor in a representative RCC patient cohort. We observed differentially regulated Gal3ST1 expression in all RCC types, being significantly more associated with clear cell RCC than to chromophobe RCC (p = 0.001). Surprisingly, in contrast to published observations from in vitro models, we could not confirm an association between Gal3ST1 expression and a malignant clinical behaviour of the RCC. In our cohort, Gal3ST1 did not significantly influence progression-free survival (Hazard Ratio (HR): 1.7 95% CI (0.6–4.9), p = 0.327). Particularly after adjusting for histology, T-stage, N-status and M-status at baseline, we observed no independent prognostic effect (HR = 1.0 95% CI (0.3–3.3), p = 0.96). The analysis of Gal3ST1 mRNA expression in a TCGA dataset supported the results of our cohort. Thus, Gal3ST1 might help to differentiate between chromophobe RCC and other frequent RCC entities but—despite previously published data from cell culture models—does not qualify as a prognostic marker for RCC. Further investigation of regulatory mechanisms of sulfatide metabolism in human RCC microenvironment is necessary to understand the role of this quantitatively prominent glycosphingolipid in RCC progression.
that about one third of the patients with RCC will show metastatic progression after curative surgery. The five-parameter multifactorial algorithm of the Memorial Sloan Kettering Center classification (MSKCC) in addition to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) are currently broadly used clinical prognostic models worldwide for metastatic RCC. Although no specific prognostic biomarkers of the RCC microenvironment have been confirmed so far, recent transcriptomic studies have identified microenvironment-associated immune components that may be associated with RCC progression. It is reasonable to assume that, like in other malignancies, dynamic changes of cellular, biophysical and biochemical factors of the RCC micromilieu may influence cancer progression. The continuing search for clinical, biochemical, immunological and histological markers of RCC has led to a better understanding of tumor biology and disease progression, albeit with limited prognostic values.

Glycosphingolipids are well established antigens recognized by unconventional T cells. Sulfatides as a prominent group of polar glycosphingolipids represent antigens for human invariant natural killer T cells. Enhanced expression of glycolipids in human RCC has been well documented decades ago. Sulfated glycosphingolipids with their major representatives galactosylsulfatide (SM4s) and lactosylsulfatide (SM3) are detected in renal tissue under physiologic conditions where they may play important regulatory roles, for instance in adaptation to metabolic acidosis. Increased expression of sulfatides in human renal cell cancer, but also in other cancer tissue and cell lines like adenocarcinoma of colon, lung, stomach and ovary may mediate metastatic spreading via binding to P-selectin and facilitate lymph node metastasis. We have previously reported a sulfatide-mediated repograming of macrophage expression profile towards a M2 (anti-inflammatory) phenotype via enhancement of apoptotic cancer cell uptake by sulfatide-coated macrophages in a murine experimental model. Moreover, we have shown that sulfatides (including complex forms SM2 and SM1a) bind to chemokines, together suggesting a complex role of sulfatides in shaping the immune landscape of RCC.

Two enzymes are crucial for the synthesis of sulfatides: in the first step, UDP-galactose ceramide galactosyltransferase (CGT) mediates synthesis of the sulfate precursor galactosylceramide (GalCer) in endoplasmatic reticulum; in the second, upon transport of GalCer to Golgi apparatus, its sulfation occurs through cerebro-sulfotransferase (CST; Gal3ST1). A recent in vitro study addressed potential pathways of Gal3ST1 overexpression in RCC and identified Gal3ST1 as a novel hypoxia-inducible factor (HIF) -mediated gene. Furthermore, employing cell culture cell of different human kidney- and kidney cancer-lines, the authors suggest a potential role of Gal3ST1 in promotion of cancer immune escape via Gal3ST1-sulfatide-mediated cancer cell-platelet interaction and thereby worse prognosis. Supporting this notion, the activation of platelets via binding of sulfatide to P-Selectin has previously been reported by other authors as well.

The aim of our study was to evaluate the prognostic value of the sulfatide-producing enzyme Gal3ST1 expression in human RCC. Based on the current literature data, we hypothesized that overexpression of Gal3ST1 detected by immunohistochemistry in paraffin sections from patients with RCC reflects the malignant potential of RCC and negatively correlates with progression-free survival (PFS). In representative study cohort, our results showed no significant correlation between the intensity of Gal3ST1 staining and cancer progression, thereby opposing published data from cell culture models and denying Gal3ST1 as an independent histological prognostic marker in the clinical setting. In addition, our analysis of TCGA dataset from patients with ccRCC, pRCC and chRCC supported the results from our patient cohort, showing no significant prognostic relevance of Gal3ST1 mRNA expression. Hence, our results indicate that potential prognostic value of (lipid) sulfatide, as an abundant and in part immunomodulating component of RCC microenvironment, cannot be translated to (enzyme / protein) Gal3ST1 levels in tumor cells.

**Results**

**Study cohort.** Out of 119 patients with RCC included in the cohort, 94 had ccRCC (79%), 17 pRCC (14%, including 10 pRCC Type 1 and 7 pRCC Type 2 cases) and 8 chRCC (7%). Median age was 64 years (34–91 years) and 71% were male (n = 85). The median follow-up was 74 Months (IQR 57–83 Months) during which 29 events occurred. 53% of tumors were resected in pT1 stage (n = 63). Lymph node metastases were present in 4% (n = 5), while 10% (n = 12) patients had distant metastases at the time of surgery. Late metastases occurred in 19% (n = 24) cases, all of them with invasion of the vein wall described in the primary histopathologic diagnosis. Clinicopathological features of the study cohort are presented in the Table 1.

**Increased expression of the enzyme Gal3ST1 can be detected in all major types of renal cell cancer but is less common in chRCC.** Paraffin sections from patients with renal malignancy (ccRCC, pRCC, chRCC) were analyzed for the localization and intensity of GAL3ST1 Expression in tumor and its microenvironment, including peritumoral kidney tissue. Specific, mainly cytoplasmic tumor cell positivity for Gal3ST1 could be detected in investigated histological cancer types, in various intensity grades (Fig. 1a,d). Tumor-free kidney (Fig. 1b) and peritumoral kidney tissue (Fig. 1c) showed typically weak to moderate Gal3ST1 expression, predominantly in tubular system (proximal > distal tubuli). Glomerular structures, blood vessels and interstitial inflammatory cells showed no specific Gal3ST1 staining, thereby serving as an internal negative control. The semi-quantitative evaluation of the intensity of expression (intensity grade—IG) was performed as described below (Fig. 1d). In general, any degree of tumor-specific Gal3ST1 positivity was evident in 81% (n = 96) cases. Out of 94 ccRCC, 86% (n = 81) were Gal3ST1 positive; the values for pRCC and chRCC were 76% (n = 13) and 25% (n = 2), respectively (Table 2). Taken together, Gal3ST1 expression was significantly less associated to chRCC than to other 2 histological types (p = 0.001; Table 2). Strong expression of Gal3ST1 (IG = 3) was detected in 36% (n = 34) ccRCC, 18% (n = 3) pRCC and 12.5% (n = 1) chRCC (Table 3). There was no association of Gal3ST1 expression with patient age; interestingly, strong Gal3ST1 expression was significantly more frequent in male than in female patients (p = 0.04; Table 2), also when accounting for histology (p = 0.04). Nevertheless,
in the TCGA dataset (described below) we could not observe a significant association between Gal3ST1 mRNA expression and gender.

**Gal3ST1 protein expression in RCC does not correlate with established pathological risk factors and is not associated with progression-free survival.** In order to investigate the association of Gal3ST1 positivity with tumor progression, we first checked the representability of our study cohort in regard to the known standard risk factors (pT- and N-stage; L-, N- and V-status; R-Status; histological grade; sarcomatoid differentiation and infiltration of renal sinus fat tissue). Prognostic value of these conventional risk categories could be confirmed in our cohort with highly significant p-values (Table 4 & suppl. Figure 1). Regarding the histological type of RCC, ccRCC showed a tendency towards worse outcome in comparison to other two entities, albeit here without statistical significance (p = 0.406; suppl. Figure 1f). The detailed relation of established prognostic factors to (PFS) probability in our cohort is shown in suppl. Figure 1.

To investigate the prognostic relevance of Gal3ST1 expression in RCC, we analyzed the association of Gal3ST1 positivity to single classical risk factors and performed univariable Cox-Regression on PFS. We employed 2 comparison modules: (1) binary module (influence of Gal3ST1 positivity in general); and (2) quantitative module (impact of Gal3ST1 appreciating the intensity of the enzyme expression). In both cases no significant association with known risk factors could be detected (Tables 2 and 3). In addition, due to a different biology and behavior of pRCC types 1 and 2, we performed separate analysis of the two entities in regard to classical prognostic factors and Gal3ST1 expression. Our results go in line with already described initial presentation of pRCC type 2 at higher stage (p = 0.02 for pT-status) and show no significant differences in the Gal3ST1 positivity (p = 1.00 for the binary model and p = 0.83 for quantitative model; Table 5). Finally, Gal3ST1 expression in our cohort had no significant influence on PFS (Fig. 2; readout parameters: cancer recurrence and late metastasis—in total 29 events, HR 1.7 95% CI (0.6–4.9)). The detailed data on impact of Gal3ST1 on PFS are presented in the Table 4. When additionally accounting for classical risk factors in multivariable Cox-model, the effect observed in univariable Cox-regression further diminished (HR: 1.03 and 1.35; Tables 6 and 7, respectively).

**mRNA expression of Gal3ST1 mRNA in TCGA cohort.** In the TCGA dataset including ccRCC (n = 534), pRCC (n = 288) and chRCC (n = 65), Gal3ST1 showed differential mRNA expression between the selected histological entities, with strongest expression in ccRCC and lowest in chRCC (p < 2.22e–16 between each RCC histotype, Fig. 3a). Subtype information of pRCC was available for only a subset of cases (Suppl. Figure 2). Similar to our cohort, no difference in expression was observed between pRCC type 1 (n = 74) and type 2 (n = 60; p = 0.7).

Interestingly, ccRCC and pRCC in the TCGA cohort showed significantly higher Gal3ST1 mRNA expression than non-neoplastic kidney tissue of the same patients, opposite to the chRCC (data not shown); still, without knowing the exact localization of the ‘normal kidney tissue’ (cortex vs. medulla), this observation should be interpreted with caution. Importantly, regarding the influence of the Gal3ST1 mRNA expression on overall

| Table 1. Clinicopathological features of the study cohort. *Data are presented as median value (with range in brackets). **According to the current WHO classification, chRCC cannot be graded due to its innate nuclear atypia. Thereby the grading values shown here relate to ccRCC and pRCC cases. |
|---------------------------------------------------------------|
| **Total number of patients** | n = 119 |
| Follow up* (months; range) | 75 (0–105) |
| Sex (male, n; %) | 85 (71.4) |
| Age* (years; range) | 64 (34–91) |
| **Histological type (n; %)** | |
| ccRCC | 94 (79) |
| pRCC | 17 (14.3) |
| chRCC | 8 (6.7) |
| **T stage (n; %)** | |
| pT1 | 63 (52.9) |
| pT2 | 18 (15.1) |
| pT3 | 36 (30.3) |
| pT4 | 2 (1.7) |
| **Grade** * (n; %) | |
| G1 | 14 (12.6) |
| G2 | 86 (77.5) |
| G3 | 11 (9.9) |
| N + (n; %) | 5 (4.2) |
| M + (at the time of surgery, n; %) | 12 (10.1) |
| M + (late, n; %) | 24 (20.5) |
survival, in the TCGA cohort we could not detect a significant effect in any of the RCC categories (p = 0.3–0.7; Fig. 3b–d), going in line with the protein expression data from our patient cohort.

Discussion

Despite a large number of investigated histological and clinical RCC features as hallmarks of malignancy, only a few have been to date confirmed and accepted as independent prognostic parameters. The role of specific parameters of RCC microenvironment in immune escape and cancer progression remains poorly described. Sulfatides are synthesized by renal tumors and can serve as tumor antigens for unconventional T cells. Appreciating a line of data on abundancy of sulfated glycosphingolipids in renal tumors and their predictive value regarding lymph node metastases in colon cancer patients, we have previously addressed the role of sulfatide on modification of renal cell cancer-associated macrophage phenotype in a murine ex vivo / in vitro model and have shown its potential immunomodulatory effect. Hence, sulfatide excess in RCC-micromilieu potentially contributes to immune escape of cancer cells and tumor progression. As lipids in general can be immunohistochemically detected only in frozen tissue samples, a question of applicability of protein components of sulfatide pathway on formalin-fixed, paraffin-embedded tissue as direct risk factors of RCC progression has been raised. Especially the first downstream component of the pathway—sulfatide-producing enzyme, Gal3ST1—has been extensively investigated in past years. Using distinct kidney tumor cell lines, recently published data convincingly show enhanced binding of Gal3ST1-expressing renal cancer cells to platelets that resulted in protection of neoplastic cells against natural killer cell-triggered cytotoxic response, thus suggesting the tumor immune escape and worse prognosis. Moreover, the authors identify HIF-mediated increased synthesis of Gal3ST1, implying the effect of hypoxic tumor microenvironment on Gal3ST1 expression. In line with these observations, pathology atlas of human cancer transcriptome reports Gal3ST1 as one of the most upregulated genes in ccRCC samples in comparison to normal kidney tissue. In an animal model employing nude mice, others report increased

![Figure 1. Immunohistochemical expression of Gal3ST1 in renal cell carcinoma. (a) cytoplasmatic and partially membranous positivity for Gal3ST1 could be observed in all common types of RCC. In this figure, Gal3ST1 expression in ccRCC and pRCC (type 1 and 2) was evaluated as highest intensity grade (IG = 3) and in shown ChRCC as IG = 1. (b) tumor-free kidney tissue typically shows physiological Gal3ST1 positivity of (proximal > distal) tubuli and negativity of glomeruli, interstitium and blood vessels. (c) peritumoral fibrotic tissue (mid part of the photomicrograph) is typically Gal3ST1 negative, while tumor (upper right corner) and peritumoral atrophic renal tubuli (lower left part) show strong or weak to moderate expression of Gal3ST1, respectively. (d) other patterns of Gal3ST1 distribution and intensity in RCC (IG—intensity grade). (a–c) HE staining – upper row, Gal3ST1 immunohistochemistry—lower row; (a,d): 200×, (b,d): 100× magnification.]
intrahepatic metastasis of hepatocellular carcinoma cells upon transfection of Gal3ST141. Considering the observations on physiological protective role of renal sulfatide in metabolic acidosis21, it is challenging to hypothesize that, in pathologic setting of neoplastic disease, increased sulfatide content represents adaptive response to typically acidic and hypoxic tumor micromilieu and indirectly influences immune landscape of the TME42. Still, the prognostic significance of direct Gal3ST1 detection in clinical RCC setting has been to date not confirmed.

We evaluated here the prognostic value of Gal3ST1 protein expression in human RCC tissue. In our patient cohort, we could not detect association of immunohistochemical Gal3ST1 expression with progression-free survival (including recurrence- and late metastasis-free survival). Also, our study showed no significant association of Gal3ST1 protein expression (appreciating different expression intensities as well) with to date well defined prognostic parameters of RCC. Despite two major statistical limitations of our cohort—relatively small sample size and heterogeneity, (1) classical risk factors showed here significant impact on the outcome and thereby confirmed the representative character of the cohort, (2) multivariate confounder-adjusted analysis showed similar results and (3) supporting our data, the analysis of mRNA expression of Gal3ST1 from an independent, larger representative TCGA dataset of RCC revealed no significant impact of Gal3ST1 on overall survival. Nevertheless, it cannot be excluded that in larger cohort with more events—metastases and/or recurrent disease cases—GalsST1 might also reach statistical significance. In addition to the prognostic significance, lower Gal3ST1 expression in chRCC in comparison to ccRCC and pRCC in our patient cohort but also in TCGA dataset suggests that this marker might help to differentiate between these entities. However, further investigation addressing diagnostic significance of Gal3ST1 in distinct histological RCC types is needed to strengthen this observation.

Finally, our results indicate that, in major histological RCC types that make > 95% of RCC cases worldwide, Gal3ST1 does not qualify as an independent prognostic marker. The possible discrepancy between previous reports (from cell culture and murine models) and results of our clinical retrospective follow-up study underscores the need to better understand the (substrate) GaLCer—(enzyme) Gal3ST1—(product) sulfatide axis in the RCC microenvironment.

Table 2. Association of intensity of Gal3ST1 expression with risk factors (Fisher’s exact test). IG intensity grade, RSF renal sinus fat infiltration.
Material and methods

Patients, sampling criteria and tissue processing. Patients included in the cohort underwent radical or partial nephrectomy in the period between February 2008 and July 2011 at the Department of Urology and Urosurgery of the Medical Centre Mannheim, University of Heidelberg. All of the patients consented to the use of their tissue in this study and the procedure was approved by the Ethic Committee of the University Medical Centre Mannheim, University of Heidelberg (Reference number: 2015-549N-MA). Clinical data were collected by chart review. Therapy, disease progression and survival follow-up were obtained by contacting the urologist and general practitioners of the respective patients. The patients received similar therapy, according to guidelines at the time of clinical presentation (TKI mono-therapy in first line). The tissue samples were routinely fixed in 4% paraformaldehyde (PFA) and consecutively embedded in paraffin to obtain the paraffin sections for standard tissue staining (hematoxylin–eosin—HE; periodic acid Schiff—PAS) and immunohistochemistry. The histological diagnosis was performed by experienced pathologists at the Institute of Pathology, Medical Centre Mannheim, University of Heidelberg according to the actual WHO classification of Tumours of the Urinary tract. For diagnostic purposes (2008–2011), cancer staging and grading was originally performed based on the criteria of the TNM Classification of Malignant Tumors at the time of diagnosis43. Tumor stage and grade was newly re-evaluated for the purpose of this study, according to the actual 8th edition of the TNM Classification (Union for International Cancer Control—UICC). Of note, in our patient cohort, no discrepancies in TNM-stage and grade could be detected when comparing criteria from different TNM editions, as approved independently by two pathologists (ZVP and SP). To avoid an overlap of formerly defined histologic RCC types with meanwhile newly introduced entities (WHO Classification of Tumours of the Urinary System and Male Genital Organs, 3rd vs. 4th Edition), only the patients with clear-cut criteria for ccRCC, pRCC and chRCC were involved in the study. Due to the absence of clearly defined diagnostic algorithm and/or to low number of patients, 3 patients with diagnosis of ‘RCC, unclassified’ and a single patient with collecting duct (ductus Bellini) carcinoma were excluded from the study. Finally, our cohort included 119 patients.

Table 3. Association of Gal3ST1 expression (negative vs. positive) with risk factors (Fisher’s exact test). *RSF renal sinus fat infiltration.
Table 4. Univariable Cox regression on progression-free survival. *IG intensity grade, RSF renal sinus fat infiltration, HR hazard ratio, LCL/UCL lower/upper 95% confidence limits, Waldp p-value of Wald test, LRTp p-value of likelihood-ratio test.

| parameter          | N     | Events | level | ref | HR   | LCL  | UCL  | Waldp | LRTp |
|--------------------|-------|--------|-------|-----|------|------|------|-------|------|
| Gal3 (binary)      | 119   | 29     | pos   | neg | 1.7  | 0.59 | 4.89 | 0.327 | 0.297 |
| Gal3 (IG)*         | 119   | 29     | 0.5   | 0   | 1.97 | 0.55 | 7.77 | 0.297 | 0.0373 |
|                    |       |        | 0     | 1   | 2.58 | 0.57 | 11.66 | 0.219 |
|                    |       |        | 2     | 0   | 2.35 | 0.72 | 7.66 | 0.158 |
|                    |       |        | 3     | 0   | 1.07 | 0.31 | 3.64 | 0.920 |
| Grade              | 111   | 28     | G2    | G1  | 3.97 | 0.54 | 29.37 | 0.177 | 0.031 |
|                    |       |        | G3    | G1  | 12.86 | 1.42 | 116.38 | 0.023 |
| T Stage            | 119   | 29     | pT2   | pT1 | 2.96 | 0.94 | 9.35 | 0.064 | <0.001 |
|                    |       |        | pT3/4 | pT1 | 7.39 | 3.02 | 18.09 | 0.158 |
| Histology          | 119   | 29     | pRCC  | ccRCC | 0.45 | 0.11 | 1.9  | 0.027 | 0.347 |
|                    |       |        | chRCC | ccRCC | 0.45 | 0.06 | 3.3  | 0.429 |
| V status           | 119   | 29     | 1     | 0   | 6.77 | 3.03 | 15.12 | <0.001 |
|                    |       |        | 2     | 0   | 5.6  | 1.59 | 19.73 | 0.007 |
| N status           | 119   | 29     | 1     | 0   | 9.32 | 3.45 | 25.16 | <0.001 |
| M status           | 119   | 29     | M1    | M0  | 21.4 | 8.01 | 57.15 | <0.001 |
| RSF*               | 119   | 29     | 1     | 0   | 4.87 | 1.66 | 14.32 | 0.004 | 0.016 |
| R status           | 116   | 28     | 1/2   | 0   | 5.63 | 1.92 | 16.48 | 0.002 | 0.009 |
| L. status          | 119   | 29     | 1     | 0   | 9.83 | 3.24 | 29.83 | <0.001 |

Table 5. Association of pRCC histotypes 1 and 2 with classical risk factors and Gal3ST1 expression (Fisher’s exact test). *Int Expression intensity.

| Parameter          | Level | pRCC type 1 | pRCC type 2 | p    |
|--------------------|-------|-------------|-------------|------|
| n                  |       | 10          | 7           | 1.000|
| Sex (%)            | m     | 8 (80.0)    | 5 (71.4)    | 1.000|
|                    | w     | 2 (20.0)    | 2 (28.6)    |      |
| Age (median [IQR]) |       | 58.50 [50.75, 66.50] | 73.00 [66.50, 73.50] | 0.157|
| T Stage (%)        | pT1   | 9 (90.0)    | 3 (42.9)    | 0.026|
|                    | pT2   | 1 (10.0)    | 1 (14.3)    |      |
|                    | pT3/4 | 0 (0.0)     | 3 (42.9)    |      |
| Grading (%)        | G1    | 3 (30.0)    | 1 (14.3)    | 0.369|
|                    | G2    | 7 (70.0)    | 4 (57.1)    |      |
|                    | G3    | 0 (0.0)     | 2 (28.6)    |      |
| N Status (%)       | 0     | 10 (100.0)  | 6 (85.7)    | 0.412|
|                    | 1     | 0 (0.0)     | 1 (14.3)    |      |
| M Status (%)       | M0    | 10 (100.0)  | 4 (57.1)    | 0.051|
|                    | M1    | 0 (0.0)     | 3 (42.9)    |      |
| V Status (%)       | 0     | 10 (100.0)  | 5 (71.4)    | 0.154|
|                    | 1     | 0 (0.0)     | 1 (14.3)    |      |
| Gal3ST1 (Int*)     | 0/0.5 | 5 (50.0)    | 3 (42.9)    | 0.665|
|                    | 1/2   | 4 (40.0)    | 2 (28.6)    |      |
|                    | 3     | 1 (10.0)    | 2 (28.6)    |      |
| Sarcomatoid morphol (%) | 0 | 10 (100.0) | 7 (100.0) | 1.000 |
|                    | 1     | 0 (0.0)     | 0 (0.0)     |      |
| R Status (%)       | 0     | 10 (100.0)  | 6 (100.0)   | 1.000 |
|                    | 1/2   | 0 (0.0)     | 0 (0.0)     |      |
| L. Status (%)      | 0     | 10 (100.0)  | 6 (85.7)    | 0.412|
|                    | 1     | 0 (0.0)     | 1 (14.3)    |      |
Immunohistochemistry and sample evaluation. For immunohistochemical Gal3ST1 staining, paraffin-embedded tissue was cut to 1-µm sections. Polyclonal rabbit anti-human Gal3ST1-antibody was applied at final concentration of 2 µg/ml. Image acquisition and analysis of immunohistochemical and H&E stained slides was done using the PreciPoint scanning microscope M8 with Olympus PlanCN 20x/0.65 Objective and MicroPoint software (v.2016-02-05; PreciPoint, Freising, Germany). Necrotic, fibrotic or hemorrhagic tumor

Table 6. Multivariable Cox regression model (n = 119, number of events = 29).

| Variable | Units | HazardRatio | CI.95       | p-value |
|----------|-------|-------------|-------------|---------|
| Gal3pos  |       |             |             |         |
| pos      |       | 1.03        | [0.33;3.25] | 0.95624 |
| Tumor stage |     |             |             |         |
| pT1      | Ref   | 1.60        | [0.45;5.65] | 0.46356 |
| pT2      | 1.60  | [0.45;5.65] | 0.46356     |         |
| pT3/4    | 3.89  | [1.38;11.00]| 0.01028     |         |
| N status |       |             |             |         |
| 0        | Ref   | 4.61        | [1.47;14.50]| 0.00887 |
| 1/2      | 4.61  | [1.47;14.50]| 0.00887     |         |
| M status |       |             |             |         |
| M0       | Ref   | 16.13       | [5.30;49.11]| < 0.001 |
| Histology |       |             |             |         |
| ccRCC    | Ref   | 0.44        | [0.09;2.22] | 0.31959 |
| chRCC    | 0.72  | [0.09;5.69] | 0.75179     |         |

Table 7. Multivariable Cox regression model (n = 111, number of events = 28).

| Variable | Units | Missing | HazardRatio | CI.95       | p-value |
|----------|-------|---------|-------------|-------------|---------|
| Gal3pos  |       | 0       |             |             |         |
| pos      |       | 1.35    | [0.37;4.85] | 0.6504     |         |
| TumorStage |      | 0       |             |             |         |
| pT1      | 0     | 1.74    | [0.50;6.12] | 0.3845     |         |
| pT2      | 1.74  | [0.50;6.12]| 0.3845      |         |
| pT3/4    | 3.76  | [1.34;10.57]| 0.0121     |         |
| N.Status |       | 0       |             |             |         |
| 0        | 0     | 3.90    | [1.23;12.35]| 0.0209    |         |
| 1/2      | 3.90  | [1.23;12.35]| 0.0209     |         |
| M.Status |       | 0       |             |             |         |
| M0       | 0     | 15.83   | [5.30;49.11]| < 0.001   |         |
| M1       | 15.83 | [5.30;49.11]| < 0.001   |         |
| Grading  |       |         |             |             |         |
| G1       | 0     | 1.93    | [0.25;15.09]| 0.5325    |         |
| G2       | 1.93  | [0.25;15.09]| 0.5325    |         |
| G3       | 2.37  | [0.22;25.96]| 0.4806    |         |

Figure 2. Kaplan–Meier curves for progression-free survival according to (a) binary expression of Gal3ST1 (positive vs negative) and (b) intensity grades of Gal3ST1 protein expression in our patient cohort.
areas were not assessed. The intensity of Gal3ST1 staining in vital tumor was evaluated by two pathologists (ZVP and SP) and scored using a semiquantitative scoring system: 0- no specific staining of tumor cells; 0.5- focal single cell staining; 1- weak patchy staining; 2- moderate staining; and 3- strong diffuse positivity. Internal positive control was physiological cytoplasmic positivity of proximal and distal tubuli.

**TCGA analysis.** RNA-Seq expression data of GAL3ST1 in primary tumor samples for the cohorts 'TCGA-KIRC' (ccRCC, n = 534), 'TCGA-KIRP' (pRCC, n = 288) and 'TCGA-KICH' (chRCC, n = 65) were downloaded from the GDC data portal using the Bioconductor package TCGAbiolinks. GAL3ST1 expression was analyzed as log2-transformed FPKM (Fragments Per Kilobase Million) values.

Overall survival (OS) was analyzed as time from diagnosis. GAL3ST1 expression was analyzed for association with OS based on Kaplan–Meier estimates and log-rank test in each cohort separately using tertile expression cut-offs.

---

**Figure 3.** (a) Analysis of Gal3ST1 mRNA expression in TCGA cohort of ccRCC (KIRC), pRCC (KIRP) and chRCC (KICH) patients. (b) Kaplan–Meier curves for overall survival probability for three histotypes from TCGA using tertile cut-offs for Gal3ST1 mRNA expression.
Informed consent. Informed consent was obtained from all participants in this study and the procedure was approved by the Ethics Committee of the University Medical Centre Mannheim, University of Heidelberg (Reference number: 2015-549N-MA). All research was performed in accordance with relevant guidelines and regulations.

Received: 12 November 2020; Accepted: 11 May 2021
Published online: 25 May 2021

References

1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin. 68(1), 7–30 (2018).
2. Teishima, J., Inoue, S., Hayashi, T. & Matsubara, A. Current status of prognostic factors in patients with metastatic renal cell carcinoma. Int. J. Urol. 26(6), 608–617 (2019).
3. Padala, S. A. et al. Epidemiology of renal cell carcinoma. World J. Oncol. 11(3), 79–87 (2020).
4. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018).
5. Hsieh, J. J. et al. Renal cell carcinoma. Nat. Rev. Dis. Primers. 3, 17009 (2017).
6. Kitamura, H. & Tsukamoto, T. Prognostic biomarkers of renal cell carcinoma: Recent advances. Indian J. Urol. 24(1), 10–15 (2008).
7. Motzer, R. J., Bacik, J. & Mazumdar, M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial sloan-kettering cancer center experience. Clin. Cancer Res. 10(18 Pt 2), 6305S–6303S (2004).
8. Motzer, R. J. et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J. Clin. Oncol. 22(3), 454–463 (2004).
9. Shinohara, N. et al. Is memorial sloan-kettering cancer center risk classification appropriate for Japanese patients with metastatic renal cell carcinoma in the cytokine era?. Urol. Oncol. 31(7), 1276–1282 (2013).
10. Heng, D. Y. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study. J. Clin. Oncol. 27(34), 5794–5799 (2009).
11. Hakimi, A. A. et al. Transcriptomic profiling of the tumor microenvironment reveals distinct subgroups of clear cell renal cell cancer: Data from a randomized phase III trial. Cancer Discov. 9(4), 510–525 (2019).
12. Wang, T. et al. An Empirical approach leveraging tumorgrafts to dissect the tumor microenvironment in renal cell carcinoma identifies missing link to prognostic inflammatory factors. Cancer Discov. 8(9), 1142–1153 (2018).
13. Wang, M. et al. Role of tumor microenvironment in tumorigenesis. J. Cancer. 8(5), 761–773 (2017).
14. Hu, S. L. et al. The Nephrologist’s tumor: Basic biology and management of renal cell carcinoma. J. Am. Soc. Nephrol. 27(8), 2227–2237 (2016).
15. Popovic, Z. V. et al. Glucosylceramide synthase is involved in development of invariant natural killer T cells. Front. Immunol. 8, 848 (2017).
16. Terabe, M. & Berzofsky, J. A. Tissue-specific roles of NKT cells in tumor immunity. Front. Immunol. 9, 1388 (2018).
17. Stax, A. M. et al. Autoreactivity to sulfatide by human invariant NKT cells. J. Immunol. 199(1), 97–106 (2017).
18. Singh, A. K., Tripathi, P. & Cardell, S. L. Type II NKT cells: An elusive population with immunoregulatory properties. Front. Immunol. 9, 1969 (2018).
19. Hakomori, S. Tumor-associated carbohydrate antigens. Annu. Rev. Immunol. 2, 103–126 (1984).
20. Sakakibara, N., Gasa, S., Kamio, K., Makita, A. & Koyanagi, T. Association of elevated sulfatides and sulfotransferase activities with human renal cell carcinoma. Cancer Res. 49(2), 335–339 (1989).
21. Stettner, P. et al. Sulfatides are required for renal adaptation to chronic metabolic acidosis. Proc. Natl. Acad. Sci. U.S.A. 110(24), 9998–10003 (2013).
22. Iida, Y. et al. Glycolipids in human lung carcinoma of histologically different types. J. Natl. Cancer Inst. 63(5), 1153–1160 (1979).
23. Kobayashi, T. et al. Sulfolipids and glycolipid sulfotransferase activities in human renal cell carcinoma cells. Br. J. Cancer. 67(1), 76–80 (1993).
24. Hattori, H., Uemura, K. & Taketomi, T. The presence of blood group A-active glycolipids in cancer tissues from blood group O patients. Biochim. Biophys. Acta. 666(3), 361–369 (1981).
25. Liu, Y. et al. Elevation of sulfatides in ovarian cancer: An integrated transcriptomic and lipidomic analysis including tissue-imaging mass spectrometry. Mol. Cancer. 9, 186 (2010).
26. Makhlof, A. M., Fatallah, M. M., Zakhary, M. A. & Makarem, M. H. Sulfatides in ovarian tumors: Clinico-pathological correlates. Int. J. Gynecol. Cancer. 14(1), 89–93 (2004).
27. Garcia, J., Callewaert, N. & Borsig, L. P-selectin mediates metastatic progression through binding to sulfatides on tumor cells. Glycobiology 17(2), 185–196 (2007).
28. Moriguchi, H., Hamanaka, Y., Tai, T. & Ishikawa, I. Sulfatides as a predictive factor of lymph node metastasis in patients with colorectal adenocarcinoma. Cancer 78(1), 43–47 (1996).
29. Popovic, Z. V. et al. Sulfated glycosphingolipid as mediator of phagocytosis: SM4s enhances apoptotic cell clearance and modulates macrophage activity. J. Immunol. 179(10), 6770–6782 (2007).
30. Sandhoff, K. et al. Chemokines bind to sulfatides as revealed by surface plasmon resonance. Biochim. Biophys. Acta. 1687(1–3), 52–63 (2005).
31. Bosio, A., Binczek, E., Le Beau, M. M., Fernald, A. A. & Stoffel, W. The human gene CGT encoding the UDP-galactose ceramide galactosyltransferase (cerebroside synthase): Cloning, characterization, and assignment to human chromosome 4, band q6. Genomics 34(1), 69–75 (1996).
32. Hirahara, Y., Iida, M., Wada, Y. & Honke, K. cDNA cloning, genomic cloning, and tissue-specific regulation of mouse cerebroside sulfotransferase. Eur. J. Biochem. 267(7), 1909–1917 (2000).
33. Honke, K. et al. Molecular cloning and expression of DNA encoding human 3′-phosphoadenosylphosphate-ceramide 3′-sulfotransferase. J. Biol. Chem. 272(8), 4864–4868 (1997).
34. Takahashi, T. & Suzuki, T. Role of sulfatide in normal and pathological cells and tissues. J. Lipid Res. 53(8), 1437–1450 (2012).
35. Robinson, C. M. et al. A hypoxia-inducible HIF1-GAL3ST1-sulfatide axis enhances ccRCC immune evasion via increased tumor cell-platelet binding. *Mol. Cancer Res.* 17(11), 2306–2317 (2019).
36. Merten, M. et al. Sulfatides activate platelets through P-selectin and enhance platelet and platelet-leukocyte aggregation. *Arterioscler. Thromb. Vasc. Biol.* 25(1), 258–263 (2005).
37. Ljungberg, B. Prognostic factors in renal cell carcinoma. *Scand. J. Surg.* 93(2), 118–125 (2004).
38. Delahunt, B., Srigley, J. R., Egevad, L., Montironi, R. & International Society for Urological Pathology. International Society of Urological Pathology grading and other prognostic factors for renal neoplasia. *Eur. Urol.* 66(5), 795–8 (2014).
39. Tán, P. H. et al. Renal tumors: Diagnostic and prognostic biomarkers. *Am. J. Surg. Pathol.* 37(10), 1518–1531 (2013).
40. Uhlen, M. et al. A pathology atlas of the human cancer transcriptome. *Science* 357, 6352 (2017).
41. Zhong, Wu. X., Honke, K., Long Zhang, Y., Liang Zha, X. & Taniguchi, N. Lactosylsulfatide expression in hepatocellular carcinoma cells enhances cell adhesion to vitronectin and intrahepatic metastasis in nude mice. *Int. J. Cancer.* 110(4), 504–510 (2004).
42. Burgdorf, S., Porubsky, S., Marx, A. & Popovic, Z. V. Cancer acidity and hypertonicity contribute to dysfunction of tumor-associated dendritic cells: Potential impact on antigen cross-presentation machinery. *Cancers (Basel).* 12, 9 (2020).
43. Sobin, L. H., Gospodarowicz, M. K. & Wittekind, C. *TNM Classification of Malignant Tumours* (John Wiley & Sons, New York, 2011).

**Acknowledgements**

We thank Katrin Wolk (Institute of Pathology, University Medical Center Mannheim) for expert technical assistance.

**Author contributions**

Z.V.P. and S.P. designed and initiated the study. Z.V.P. wrote the manuscript. S.P. provided critical input to shape the manuscript. T.H. analysed data and provided critical feedback. M.N., M.C.K. and P.E. contributed clinical data. J.H.H.S., C.A.W., R.S., R.J., H.B. and T.G. participated in data interpretation. All authors helped shape the manuscript and approved the final version.

**Funding**

Open Access funding enabled and organized by Projekt DEAL.

**Competing interests**

The authors declare no competing interests.

**Additional information**

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-90381-6.

Correspondence and requests for materials should be addressed to Z.V.P.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021